PRRT/PRCRT后治疗相关髓系肿瘤的特征与结局
该单中心回顾性研究分析了521例接受PRRT/PRCRT的转移性神经内分泌肿瘤患者,其中25例(4.8%)发生治疗相关髓系肿瘤(t-MN)。t-MN诊断后中位总生存仅13个月,多数患者以血小板减少起病,不良核型及TP53突变常见,对t-MN治疗反应差。
要点
- PRRT/PRCRT后t-MN发生率为4.8%,中位潜伏期26个月。
- t-MN诊断时均出现血小板减少,68%患者NEN仍无进展。
- t-MN诊断后中位总生存仅13个月,主要死于血液病进展。
核心结论
- PRRT/PRCRT后t-MN虽不常见但为严重并发症,总生存差。
- 多数t-MN患者以血小板减少起病,不良遗传学突变对t-MN治疗反应差。
研究设计与样本
- 单中心回顾性分析12年间接受PRRT/PRCRT的521例转移性NEN患者。
- 按2016 WHO分类诊断t-MN,并进行26基因 panel 二代测序。
主要发现
- 25/521(4.8%)发生t-MN,其中6例AML、19例MDS。
- 从首次PRRT/PRCRT至t-MN诊断中位时间26个月(范围4-91)。
- 25例中22例(88%)为1-2级胰腺或小肠NEN伴中度肝转移负荷,6例(24%)有既往化疗史。
- PRRT中位周期数5,22/25(88%)同期接受放射增敏化疗;PRRT后3个月按RECIST 1.1全部达疾病稳定(68%)或部分缓解(32%)。
- t-MN诊断时全部患者血小板减少(中位最低值33×10^9/L,范围3-75),17例(68%)NEN仍无进展;16/25(66%)核型不良,9例(36%)TP53突变。
关键数值与推荐
- t-MN诊断依据2016 WHO分类。
- 10例符合条件的t-MN患者接受阿扎胞苷治疗,4例AML接受诱导化疗。
临床怎么用
- PRRT/PRCRT后应监测血细胞减少,尤其血小板减少,警惕t-MN。
- 对疑似t-MN应进行骨髓遗传学分析,不良核型及TP53突变提示治疗反应差。
- t-MN诊断后预后极差,需权衡t-MN治疗与NEN管理。
局限性
- 单中心回顾性设计,样本量有限。
- 缺乏前瞻性数据验证预存遗传因素及预测生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) is an effective therapy for metastatic neuroendocrine neoplasia (NEN), but therapy-related myeloid neoplasms (t-MN) remain of concern. The study reviewed the clinicopathological features and outcomes of patients who developed t-MN. METHODS: Retrospective analysis of all patients diagnosed with t-MN by 2016 WHO classification, from a cohort of 521 patients who received PRRT/PRCRT over a 12-year period. Molecular next-generation sequencing using an in-house 26-gene panel was performed. RESULTS: Twenty-five of 521 (4.8%) patients were diagnosed with t-MN, including six acute myeloid leukaemia (AML) and 19 myelodysplastic syndrome (MDS). The median time from first cycle PRRT/PRCRT to diagnosis of t-MN was 26 months (range 4-91). Twenty-two of 25 (88%) patients had grade 1-2 pancreatic or small bowel NEN with moderate metastatic liver burden. Six patients (24%) had prior chemotherapy. Median number of PRRT cycles = 5 (22/25 (88%) with concomitant radiosensitising chemotherapy). All 25 patients achieved disease stabilisation (68%) or partial response (32%) on RECIST 1.1 at 3 months post-PRRT. At t-MN diagnosis, all patients presented with thrombocytopenia (median nadir 33 × 109/L, range 3-75) and 17 (68%) remained NEN progression-free. Marrow genetic analysis revealed unfavourable karyotype in 16/25 (66%) patients with tumour protein 53 (TP53) mutation in nine (36%). Azacitidine therapy was utilised in ten eligible patients, while four received induction chemotherapy for AML. The median overall survival from first PRRT was 62 months (19-94), but from t-MN diagnosis was only 13 months (1-56), with death due primarily to haematological disease progression. CONCLUSIONS: The diagnosis of t-MN after PRRT/PRCRT is an infrequent but serious complication with poor overall survival. Most patients present with thrombocytopenia; unfavourable genetic mutations have a poor response to t-MN treatment. Prospective data are needed to explore potential pre-existing genetic factors and predictive biomarkers to minimise the risk of t-MN.
引用
- Goncalves I, Burbury K, Michael M, et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging. 2019. PMID: 31187162. doi:10.1007/s00259-019-04389-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。